Literature DB >> 17948896

Replication study and meta-analysis of the genetic association of GRM3 gene polymorphisms with schizophrenia in a large Japanese case-control population.

Talal Albalushi1, Yasue Horiuchi, Hiroki Ishiguro, Minori Koga, Toshiya Inada, Nakao Iwata, Norio Ozaki, Hiroshi Ujike, Yuichiro Watanabe, Toshiyuki Someya, Tadao Arinami.   

Abstract

The GRM3 gene, which encodes a metabotropic glutamate receptor, is an important candidate gene for susceptibility to schizophrenia. Two single nucleotide polymorphisms (SNPs), rs1468412 and rs2299225 in intron 3, were reported to be associated with schizophrenia in Japanese and Chinese populations, respectively. Haplotypes with these SNPs were also reported to be associated with schizophrenia. In the present study, we attempted to replicate these single marker and haplotype associations in a case-control study of 1,916 Japanese patients with schizophrenia and 1,915 Japanese control subjects. In addition to these two SNPs, we genotyped rs274622 in the promoter region of GRM3. In the present study, none of these polymorphisms were associated with schizophrenia (rs274622, allelic P = 0.68; rs1468412, allelic P = 0.74; rs2299225, allelic P = 0.20). Haplotypes constructed with these SNPs also were not associated with schizophrenia (P = 0.18-0.84). Meta-analysis of five case-control studies of more than 3,000 patients with schizophrenia and more than 3,000 control subjects did not support the associations of rs1468412 and rs2299225 with schizophrenia. Our data indicate that SNPs previously reported to be associated with schizophrenia do not contribute to genetic susceptibility to schizophrenia. Copyright 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17948896     DOI: 10.1002/ajmg.b.30610

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  9 in total

1.  Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia.

Authors:  Jeffrey R Bishop; Del D Miller; Vicki L Ellingrod; Timothy Holman
Journal:  Hum Psychopharmacol       Date:  2011-01       Impact factor: 1.672

Review 2.  Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists.

Authors:  John H Krystal; Sanjay J Mathew; D Cyril D'Souza; Amir Garakani; Handan Gunduz-Bruce; Dennis S Charney
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

Review 3.  Group II metabotropic glutamate receptors and schizophrenia.

Authors:  José L Moreno; Stuart C Sealfon; Javier González-Maeso
Journal:  Cell Mol Life Sci       Date:  2009-08-26       Impact factor: 9.261

4.  Comprehensive behavioral study of mGluR3 knockout mice: implication in schizophrenia related endophenotypes.

Authors:  Ryuta Fujioka; Takenobu Nii; Akiko Iwaki; Atsushi Shibata; Isao Ito; Kiyoyuki Kitaichi; Masatoshi Nomura; Satoko Hattori; Keizo Takao; Tsuyoshi Miyakawa; Yasuyuki Fukumaki
Journal:  Mol Brain       Date:  2014-04-23       Impact factor: 4.041

5.  Association of metabotropic glutamate receptor 3 gene polymorphisms with schizophrenia risk: evidence from a meta-analysis.

Authors:  Xiaoqin Yang; Guiping Wang; Yaodong Wang; Xia Yue
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-25       Impact factor: 2.570

6.  Meta-analysis supports GWAS-implicated link between GRM3 and schizophrenia risk.

Authors:  S M Saini; S G Mancuso; Md S Mostaid; C Liu; C Pantelis; I P Everall; C A Bousman
Journal:  Transl Psychiatry       Date:  2017-08-08       Impact factor: 6.222

7.  Metabotropic glutamate receptor 3 is associated with heroin dependence but not depression or schizophrenia in a Chinese population.

Authors:  Wei Jia; Rui Zhang; Bin Wu; Zun-xiao Dai; Yong-sheng Zhu; Ping-ping Li; Feng Zhu
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

Review 8.  The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia.

Authors:  Carlo Maj; Alessandra Minelli; Edoardo Giacopuzzi; Emilio Sacchetti; Massimo Gennarelli
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

9.  PCM1 is necessary for focal ciliary integrity and is a candidate for severe schizophrenia.

Authors:  Tanner O Monroe; Melanie E Garrett; Maria Kousi; Ramona M Rodriguiz; Sungjin Moon; Yushi Bai; Steven C Brodar; Karen L Soldano; Jeremiah Savage; Thomas F Hansen; Donna M Muzny; Richard A Gibbs; Lawrence Barak; Patrick F Sullivan; Allison E Ashley-Koch; Akira Sawa; William C Wetsel; Thomas Werge; Nicholas Katsanis
Journal:  Nat Commun       Date:  2020-11-19       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.